Monopar Therapeutics Inc.
General ticker "MNPR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $492.0M (TTM average)
Monopar Therapeutics Inc. follows the US Stock Market performance with the rate: 39.9%.
Estimated limits based on current volatility of 3.3%: low 69.18$, high 73.92$
Factors to consider:
- Total employees count: 22 (+37.5%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: May never become profitable, Regulatory and compliance, Clinical trial failure, Operational and conduct risks, Market competition
- Current price 19.1% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [25.77$, 58.17$]
- 2026-12-31 to 2027-12-31 estimated range: [18.13$, 43.45$]
Financial Metrics affecting the MNPR estimates:
- Negative: with PPE of -37.4 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Investing cash flow per share per price, % of -12.57 <= -11.23
- Negative: Shareholder equity ratio, % of 97.95 > 81.92
- Negative: negative Industry operating cash flow (median)
Short-term MNPR quotes
Long-term MNPR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $8.83MM | $16.16MM | $16.70MM |
| Operating Income | $-8.83MM | $-16.16MM | $-16.70MM |
| Non-Operating Income | $0.43MM | $0.58MM | $2.99MM |
| R&D Expense | $5.60MM | $13.01MM | $9.90MM |
| Income(Loss) | $-8.40MM | $-15.59MM | $-13.72MM |
| Net Income(Loss)* | $-8.40MM | $-15.59MM | $-13.72MM |
| Stockholders Equity | $5.59MM | $55.04MM | $137.83MM |
| Assets | $7.35MM | $60.29MM | $140.72MM |
| Operating Cash Flow | $-7.86MM | $-6.40MM | $-12.20MM |
| Investing Cash Flow | $4.93MM | $-14.34MM | $-63.45MM |
| Financing Cash Flow | $2.03MM | $59.29MM | $91.57MM |
| Earnings Per Share** | $-0.58 | $-1.36 | $-1.85 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.